… Abstract: Parkinson’s disease is a neurodegenerative … used in the pharmacotherapy of
Parkinson’s disease, with a look at their … for their therapeutic potential in Parkinson’s disease and …

… of the disease and evaluation of therapeutics against this devastating disease difficult. Here,
… are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in …

… Hence, immunomodulation might be a possible therapeutic avenue for PD. … system, to
reduce pro-inflammatory toxicity, may provide a novel therapeutic avenue for PD treatment. …

… by Parkinson’s disease. The synergic advances in these fields permit the elaboration of
multiple therapeutic … This review discusses the features of Parkinson’s disease, the autophagy …

… Therefore a major avenue that has opened recently involves mating the advances in GWAS
study with … with various disease mechanisms and for subsequent therapeutic interventions. …

… to the understanding of Parkinson’s disease pathogenic mechanism. Also discussed are
potential therapeutic strategies that are being studied, including disease-modifying and …

… possible avenue for target validation for PD therapeutics (14). The presence of α-synuclein
as a major component of LB, familial α-synuclein mutations, gene multiplication, and protein …

Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that currently
affects 1% of the population over the age of 60 years, and for which no disease-modifying …

… As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging.
These include treatments that aim to control the symptoms of PD without the problematic side …

… Carriers of GBA1 variants have an increased risk of developing Parkinson disease (PD),
with odds ratio ranging from 2.2 to 30 according to variant severity. GBA1 variants which do not …